Search

Your search keyword '"Mazzuca, M."' showing total 246 results
Start Over Author "Mazzuca, M."
246 results on '"Mazzuca, M."'

5. Effects of helical distortions on the optical properties of amide NH infrared absorption in short peptides in solution

Author

Pispisa, B.; Palleschi, A., Stella, L.; Venanzi, M., Mazzuca, M., Formaggio, F., and Toniolo, C.; Broxterman, Q.B.

Subjects
Molecular structure -- Analysis, Hydrogen bonding -- Observations, Amides -- Optical properties, Amides -- Chemical properties, Amides -- Spectra, Chemicals, plastics and rubber industries
Abstract

The relationship between distorted intramolecular H-bonds and infrared absorption properties of the donor NH group in short helical peptides in solution are presented. The helical backbone in the peptides experiences distortions, the extent of which depends on the chain length, that are reflected in both the energy of the stretching mode and the molar extinction coefficient of the intramolecularity H-bonded N-H groups.

Published
2002

25. Canaux ioniques et épilepsies

Author

Mazzuca, M., Lesage, F., Institut de pharmacologie moléculaire et cellulaire (IPMC), Université Nice Sophia Antipolis (... - 2019) (UNS), and COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Centre National de la Recherche Scientifique (CNRS)

Published
2004

26. Storia ed evoluzione della banca dell’osso

Author

Monteleone, M, Mazzuca, M, Monteleone, G, Oliva, F, and Venanzi, R

Subjects
chistoria, banca dell’osso, innesto, chistoria, graft, Settore MED/33 - Malattie Apparato Locomotore, bone banking, history, innesto, banca dell’osso, bone banking, graft, history
Published
2002

27. [Gonadotropi adenoma linking labeled somatostatin analogs. Lack of relationship with therapeutic effect]

Author

Evrard A, Mc, Vantyghem, Damien Huglo, Hober C, Marchandise X, Mazzuca M, and Lefebvre J

Subjects
Adenoma, Pituitary Hormones, Antineoplastic Agents, Hormonal, Gonadotropins, Pituitary, Humans, Female, Pituitary Neoplasms, Postoperative Period, Middle Aged, Octreotide, Radionuclide Imaging, Combined Modality Therapy
Abstract

Somatotropin- and thyrotropin-secreting adenomas are well known for positive uptake of radio-labeled octreotide in vivo, this fact is not so well assessed for gonadotropin-secreting adenomas (GSA). We report one case of positive somatostatin receptor scintigraphy in a woman suffering from histologically proven GSA. This 63 year old patient has been suffering for two years of akinetic syndrome when the outcome of diplopia led to the discovery of a large hypophyseal tumor spreading till V3 floor and in left cavernous sinus by resonance magnetic imaging (RMI). Clinical examination showed anterior hypopituitarism and bitemporal hemianopsia. Biologically, blood gonadotropins were decreased more on LH (0.6 UI/l, N15) than on FSH (10 UI/l; N20). A lack of response of gonadotropins to LHRH with low blood estradiol concentration (10 pg/ml) was noticed. Basal blood measurement of alpha subunit was at 0.17 microgram/l (N = 0.10-1.6) and increased at 0.39 microgram/l after stimulation by LHRH. Although in low range of normal values, other hypophyseal hormones were normal except prolactinemia (45 mg/L; N20), however stimulated by TRH and related to dopaminergic deconnection; Indium 111 labeled octreotide scintigraphy showed an over uptake of the tumor. Three month treatment by octreotide (100 micrograms x 3/day subcutaneously) did not allow to decrease significantly FSH concentration or to reduce the tumoral mass. Incomplete removal of the tumor was performed by transphenoidal route. Immunohistochemical analysis revealed positive immunostaining for alpha subunit and FSH beta on numerous cells while the labeling was slightly less strong for LH beta. These data evoked a GSA. This case record depicts the possibility of detection of GSA by somatostatin receptor imaging. However a positive result does not preclude of somatostatin analog therapeutic efficiency.

Published
1996

50. TREK-1, a K+ channel involved in neuroprotection and general anesthesia.

Author

Heurteaux, C., Guy, N., Laigle, C., Blondeau, N., Duprat, F., Mazzuca, M., Lang-Lazdunski, L., Widmann, C., Zanzouri, M., Romey, G., and Lazdunski, M.

Subjects
POTASSIUM channels, ION channels, NEUROTRANSMITTERS, EPILEPSY, BRAIN diseases, FATTY acids, G proteins
Abstract

TREK-1 is a two-pore-domain background potassium channel expressed throughout the central nervous system. It is opened by polyunsaturated fatty acids and lysophospholipids. It is inhibited by neurotransmitters that produce an increase in intracellular cAMP and by those that activate the Gq protein pathway. TREK-1 is also activated by volatile anesthetics and has been suggested to be an important target in the action of these drugs. Using mice with a disrupted TREK-1 gene, we now show that TREK-1 has an important role in neuroprotection against epilepsy and brain and spinal chord ischemia. Trek1-/- mice display an increased sensitivity to ischemia and epilepsy. Neuroprotection by polyunsaturated fatty acids, which is impressive in Trek1+/+ mice, disappears in Trek1-/- mice indicating a central role of TREK-1 in this process. Trek1-/- mice are also resistant to anesthesia by volatile anesthetics. TREK-1 emerges as a potential innovative target for developing new therapeutic agents for neurology and anesthesiology. [ABSTRACT FROM AUTHOR]

Published
2004
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results